Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

PATH-2 logo

THE PATH-2 Study is a trial of platelet rich plasma (PRP) as a non-surgical treatment for Achilles tendon rupture. PRP is blood plasma containing a high concentration of platelets, specialised blood cells involved in wound repair. Eligible patients are randomised to receive standard non-operative care, or standard care plus PRP injection. Our primary outcome is an objective test of ankle function conducted at 6 months after treatment by a blinded physiotherapist assessor. This is the first large double-blinded randomised controlled trial of PRP in tendons.

In September 2017 the PATH-2 Study reached its target of 230 participants, recruited at outpatient clinics in 18 hospitals in England and Wales. PATH-2 is funded by EME, a partnership of the National Institute for Health Research and the Medical Research Council (EME reference 12/206/30).

For more information visit https://path2.octru.ox.ac.uk/ or contact the team at path-2.study@ndorms.ox.ac.uk.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.